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Previewsthrough AKT1 and INPP4B/PTEN func-
tioning through AKT2. Precisely how
this specificity is achieved remains to
be determined, although compartmen-
talization of both the lipid phosphatase
and AKT isoform is likely to play a major
role (Kofuji et al., 2015). It is also
possible that AKT2 is preferentially acti-
vated by local pools of PtdIns(3,4)P2,
such that, when PIPP is absent, less
PtdIns(3,4)P2 is generated and AKT1 be-
comes the dominantly active isoform
(Figure 1B).
There are therapeutic implications for
the finding that AKT1 drives the PIPP
phenotype. Small molecule inhibitors tar-
geting both PI3K and AKT are currently
under clinical evaluation (Fruman and
Rommel, 2014). However, notably, there
are no AKT isoform-selective compounds
that are under development. Although it
remains unclear whether such inhibitors
can be developed with acceptable drug
properties and efficacies, the notion
that AKT isoform-selective activity couldaffect clinical outcome advocates for the
development of such compounds. Also,
although reduced PIPP message levels
are observed in breast cancer and corre-
lated with ER status, because there are
no significant genomic alterations in
PIPP/INPP5J according to TCGA, it is
likely that epigenetic mechanisms ac-
count for the alterations reported by
Ooms et al. (2015). Moreover, because
PIPP is one of ten distinct mammalian 50
lipid phosphatases, future studies that
apply the approaches used to deduce
the tumor suppressor activity of PIPP on
AKT1 function in breast and other solid tu-
mors will likely shed much more light on
the complexities of PI3K and AKT function
in cancer.REFERENCES
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In this issue of Cancer Cell, Herrero and colleagues identify an anti-tumorigenic small molecule that blocks
ERK dimerization, but neither its catalytic activity nor its phosphorylation by MEK. These findings demon-
strate that targeting protein dimerization could be a therapeutic avenue for inhibiting kinase signaling path-
ways associated with lower drug resistance.The ERK/mitogen-activated protein ki-
nase (MAPK) signaling pathway inte-
grates a wide range of signals into major
cellular programs such as proliferation,
differentiation, or apoptosis. Canonical
ERK signaling is initiated upon stimulation
of the small GTPase Ras, which triggers a
sequential three-kinase phosphorylation
cascade through RAF, MEK, and ERK to
enact focused and large-scale cellular
changes. Half of all human malignancies
display aberrations in the Ras-RAF-
MEK-ERK pathway, revealing the extent
of its regulatory reach. To date, prome-thean effort has been expended identi-
fying small molecule inhibitors of this
pathway, because promising compounds
are hampered by significant side effects
and rapid development of drug resistance
(Little et al., 2013).
Sometimes overlooked, kinases are
more than phosphate-transferring en-
zymes. Many exhibit catalytic activity-
independent protein-protein interactions
that are important for context-appro-
priate signal regulation. In addition
to phosphorylating substrates, kinases
serve as binding partners for othersignaling molecules. Indeed, the MAPK
signaling scaffold protein KSR, a RAF
homolog that lacks the catalytic lysine,
tethers RAF, MEK, and ERK and can
induce changes in RAF activity allosteri-
cally (Stewart et al., 1999; Rajakulendran
et al., 2009). Allosteric regulation of ki-
nases is not limited to scaffolds or pseu-
dokinases, because RAF can regulate
itself through dimerization (Lito et al.,
2013). Regulated protein-protein inter-
actions are critical for reducing entropic
barriers to signaling. Although this
makes them tempting for drug design,, August 10, 2015 ª2015 Elsevier Inc. 145
Figure 1. A Small Molecule Inhibitor of ERK
Dimerization Can Tip the Balance of Its Downstream
Signaling Output
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Previewsprotein-protein interactions have
long been considered challenging
targets due, in part, to large molec-
ular surfaces that must be dis-
rupted by a small molecule (Whitty
and Kumaravel, 2006). In this issue
of Cancer Cell, Herrero et al.
(2015) succeeded in finding such a
molecule and demonstrated that
inhibition of ERK dimerization, but
not catalytic activity, effectively re-
routes tumorigenic signals toward
programmed cell death (Figure 1).
Methods to distinguish different
oligomeric forms of ERK are not
readily adaptable to large-scale
drug screening (Khokhlatchev
et al., 1998; Casar et al., 2008).
Thus, Herrero et al. (2015) used
native gel electrophoresis as a me-
dium-throughput assay to discrimi-
nate ERK monomers from dimersin HEK293 cells. By screening a library
of 650 compounds pre-selected to
have affinity for kinases, they identified
DEL-22379 as a small molecule capable
of inhibiting ERK dimerization without
affecting EGF-stimulated ERK phos-
phorylation. The authors confirmed that
DEL-22379 inhibited dimerization by gel
filtration, analytical ultracentrifugation,
co-immunoprecipitation, and proximity-
ligation assays. The activity of the small
molecule against a large kinase panel
indicated little cross-reactivity. ERK ki-
nase activity was unaffected by DEL-
22379 in vitro, and monomeric ERK
mutants were also active in vitro. Earlier
studies reported that inhibition of cyto-
plasmic ERK signaling by blocking
dimerization was due to impaired scaf-
folding, which was suggested to direct
proliferative responses (Casar et al.,
2008). It seems possible that cyto-
plasmic substrates not related to prolif-
erative responses are still recognized
by ERK monomers. Perhaps phosphory-
lation of these substrates also con-
tributes to the shift toward growth
suppression.
Because of the prevalence of dysregu-
lated Ras-ERK signaling in human malig-
nancies, the authors examined drug
efficacy in the context of K- or N-Ras
and BRAF mutations, in which high ERK
activity drives cell proliferation and con-
comitant tumor progression (Herrero
et al., 2015). Importantly, they demon-
strate that DEL-22379 reduces tumor146 Cancer Cell 28, August 10, 2015 ª2015 Egrowth in diverse model systems more
effectively than inhibitors of the catalytic
activities of kinases in this cascade (Little
et al., 2013). They conclude that, by
blocking dimerization, DEL-22793 dis-
rupts cytoplasmic signaling and promotes
apoptosis over proliferation. Casar et al.
(2008) previously reported that ERK di-
mers are essential for activation of
cytoplasmic, but not nuclear substrates,
and that preventing ERK dimerization
inhibited proliferation. In keeping with
these earlier findings, Herrero et al.
(2015) find that DEL-22379 increases
phosphorylation of transcription factor
substrates and, at the same time, phos-
phorylation of the ERK substrate protein
kinase RSK, often in the cytoplasm, is
decreased.
This study raises several pressing
questions. Why is this inhibitor still effec-
tive under conditions that promote resis-
tance to molecules targeting RAF, MEK,
or ERK catalytic activities? A key mecha-
nism underlying resistance to pathway
inhibitors is the loss of ERK-mediated
negative feedback exerted on multiple
proteins upstream in the pathway and
particularly on RAF itself (Lito et al.,
2013). These feedback mechanisms
include direct inhibitory phosphorylation,
phospho-activation of negative regula-
tors, and induction of inhibitory proteins.
The absence of feedback creates inhibi-
tor escape mechanisms, leading to
strong ERK activation. Given the distur-
bance in dimeric ERK signaling causedlsevier Inc.by DEL-22379, one might anticipate
that these feedback events, most of
which occur in the cytoplasm, are
also disabled. The current studies
were not directed toward ERK feed-
back, but the answer is likely to pro-
vide more insight into the mecha-
nisms of ERK pathway regulation.
Perhaps greater understanding will
come from determining how the
compound binds ERK. Herrero
et al. (2015) present a model of the
compound docked onto a groove
partially overlapping with the ERK
dimer interface (Khokhlatchev
et al., 1998). This binding mode is
clearly supported by mutagenesis
of residues in the groove, yet DEL-
22379 came from a library of mole-
cules, most of which interact with
protein kinase active sites. The allo-
steric potential of protein kinasecores in general, and ERK in particular,
suggests that a molecule that partially
overlaps the active site or other regula-
tory sites may influence protein-protein
interactions (Goldsmith et al., 2007;
Taylor and Kornev, 2011). A high resolu-
tion structure of DEL-22379 bound to
ERK2 will clarify how it blocks ERK
dimerization.
Whatever the mechanism, DEL-22379
will be a valuable research tool for re-
vealing more about oligomerization dy-
namics in ERK signaling. Small molecules
such as DEL-22379 may prove useful in
targeting compartment-specific modes
of kinase signaling, thus deepening our
basic understanding of signaling and
leading to exciting therapeutic avenues
for blocking signaling pathways. Herrero
et al. (2015) now demonstrate the power
of targeting ERK dimerization with a
novel small molecule. The finding that
DEL-22379 prevents tumor growth in
mouse and patient-derived xenograft
models provides evidence that targeting
protein-protein interactions can be effec-
tive in vivo and foreshadows promise in
developing similar compounds for clinical
studies.REFERENCES
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Myeloid-derived suppressor cells (MDSCs) play a major role in cancer. MDSC expansion is closely associ-
ated with tumor progression, but molecular mechanisms of this expansion remain poorly understood. In
this issue of Cancer Cell, Strauss and colleagues describe the roles of the nuclear receptor ROR1C in the
regulation of MDSC differentiation and expansion.The accumulation of non-lymphoid sup-
pressive cells in cancer was first reported
in the late 1970s, but these cells had at-
tracted very little attention until 15 years
ago, when their potential contribution
to tumor progression became apparent.
These cells have been named myeloid-
derived suppressor cells (MDSCs) to
reflect their origin and major functional
feature—the ability to suppress T cell acti-
vation and function. In addition, the role of
MDSCs in promoting tumor growth by
supporting angiogenesis, tumor cell sur-
vival, metastases, and formation of pre-
metastatic niches has been established
(Condamine et al., 2015). Recent studies
have provided ample evidence of the clin-
ical relevance of MDSCs (Messmer et al.,
2015). MDSCs are phenotypically distinct
from terminally differentiated dendritic
cells (DCs) and macrophages and repre-
sent a heterogeneouspopulation of imma-
ture myeloid cells that include cells with
granulocytic and monocytic morphology
and phenotype. MDSCs are now divided
into two major populations: polymor-
phonuclear-MDSCs (PMN-MDSCs) and
monocytic-MDSCs (M-MDSCs) (Mova-
hedi et al., 2008; Youn et al., 2008). In a
majority of cancer types, PMN-MDSCs,which have a phenotype and morphology
similar to those of neutrophils, represent
70%–80% of the total MDSC popula-
tion. However, in contrast to neutrophils,
PMN-MDSCs suppress T cell functions
and have a distinct gene expression pro-
file and a number of distinct functional
characteristics. M-MDSCs share their
phenotype and morphology with normal
monocytes. In contrast to spleen mono-
cytes in naive mice and blood monocytes
in healthy individuals, M-MDSCs have a
potent ability to suppress T cell functions,
which ismediated by arginase-1, nitric ox-
ide (NO), and different soluble factors
(Gabrilovich et al., 2012). MDSCs arise
from a common myeloid progenitor.
Their development is supported by the
same growth factors that are responsible
for the normal myelopoiesis: granulo-
cyte macrophage colony-stimulating fac-
tor (GM-CSF), granulocyte colony-stimu-
lating factor (G-CSF), and macrophage
colony-stimulating factor (M-CSF) (Bayne
et al., 2012; Dolcetti et al., 2010; Kowanetz
et al., 2010). However, simple expansion
of myeloid cells is not sufficient to
generate bona fide MDSCs. MDSCs exist
in the state of pathological activation,
which is the result of persistent stimulationof themyeloid compartmentwith relatively
low strength signals coming from tumors
or sites of chronic inflammation. Myeloid
cells generated under these conditions
are unable to effectively differentiate into
mature myeloid cells, are poorly phago-
cytic, and produce high levels of reactive
oxygen species, myeloperoxidase, nitric
oxide, andmostly anti-inflammatory cyto-
kines. As a result, these cells acquire
potent immune suppressive potential.
The molecular mechanisms that govern
such pathological expansion are sub-
jects of intense investigations. Different
factors were implicated in this process.
They include signal transducer and acti-
vator of transcription 3 (STAT3) and 5,
NF-kB, paired immunoglobulin-like re-
ceptor B, CCAAT/enhancer binding pro-
tein b (C/EBPb), interferon regulatory fac-
tor 8 (IRF8), retinoblastoma protein (Rb),
and other. In this issue of Cancer Cell
Strauss et al. (2015) identified novelmech-
anisms that involved RORC1.
RORC1and its splicevariantRORC2are
master regulators of IL-17A gene tran-
scription. Authors were interested in
RORC1 because they found increased
expression of IL-17A by PMN-MDSCs in
tumor-bearing mice, although these cells, August 10, 2015 ª2015 Elsevier Inc. 147
